Stockreport

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 [Read more]